Wolfgang Jungraithmayr | Medicine and Dentistry | Lifetime Achievement Award

Posted on by Phenomenological Research

Lifetime Achievement Award

Wolfgang Jungraithmayr
University Hospital of Rostock, Germany

Wolfgang Jungraithmayr
Researcher Wolfgang Jungraithmayr
Affiliation University Hospital of Rostock
Country Germany
Scopus ID 25621008100
Documents 129
Citations 2,929
h-index 28
Subject Area Medicine and Dentistry
Event International Phenomenological Research Awards
ORCID 0000-0002-1442-4862

Wolfgang Jungraithmayr, MD, PhD, is a German thoracic surgeon, clinician-scientist, educator, and academic leader serving as Chair and Full Professor of Thoracic Surgery at the University Hospital of Rostock. His research portfolio spans lung transplantation, thoracic oncology, immunology, translational medicine, and experimental surgery. He is particularly recognized for pioneering the orthotopic mouse lung transplantation model and for advancing translational research into lung cancer immunotherapy and transplant immunology.[1]

Abstract

This article evaluates the scholarly achievements, research leadership, educational contributions, and international influence of Wolfgang Jungraithmayr in the fields of thoracic surgery, lung transplantation, and translational oncology. His work integrates clinical practice with experimental science, contributing to advances in transplant immunology, lung cancer therapeutics, and surgical innovation. Through sustained research productivity, competitive grant acquisition, international collaboration, and extensive scientific mentorship, he has established a distinguished academic profile suitable for consideration for lifetime recognition within the biomedical sciences.[1]

Keywords

Thoracic Surgery; Lung Transplantation; Lung Cancer; Immunology; Translational Medicine; CD26; Experimental Surgery; Academic Leadership; Oncology; Lifetime Achievement.

Introduction

Wolfgang Jungraithmayr has developed an interdisciplinary academic career combining thoracic surgical practice, translational biomedical research, and university-level education. Following medical training in Germany and advanced specialization in Switzerland, he completed doctoral research in immunology at the University and ETH Zurich. His subsequent appointments included leadership positions at the University Hospital Zurich, Medical University Brandenburg, and University Hospital Rostock, where he currently serves as Chair of Thoracic Surgery.[2]

His scientific activities have focused on improving outcomes in lung transplantation, understanding immune-mediated disease mechanisms, and identifying novel therapeutic targets for thoracic malignancies. These efforts have produced a substantial body of peer-reviewed literature and attracted significant competitive funding from European research agencies.[1]

Research Profile

Wolfgang Jungraithmayr’s research program centers on lung transplantation biology, transplant tolerance, tumour immunology, and translational thoracic oncology. A major contribution of his laboratory has been the establishment and dissemination of the orthotopic mouse lung transplantation model, which has become a valuable experimental platform for investigating immune responses, rejection mechanisms, and therapeutic interventions across multiple disciplines.[3]

His laboratory has secured more than €3.2 million in competitive research funding, including support from the German Research Foundation (DFG), Swiss National Science Foundation (SNSF), and other major funding bodies. Research projects have addressed chronic lung allograft dysfunction, immune regulation, magnetic resonance imaging applications, angiogenesis, and targeted immunotherapeutic approaches against lung adenocarcinoma.[1]

Research Contributions

Wolfgang Jungraithmayr’s principal research contributions include pioneering murine lung transplantation models, advancing transplant immunology, investigating immune tolerance mechanisms, identifying novel therapeutic targets in lung cancer, and improving understanding of ischemia-reperfusion injury and chronic allograft dysfunction.[2][4][5][6]

Publications

Recent publications highlight Jungraithmayr’s contributions to transplantation immunology, lung transplant outcomes, ischemia-reperfusion injury, and experimental models of chronic allograft dysfunction, demonstrating sustained impact in thoracic surgery and translational research.[2][3][4][5][6]

Wolfgang Jungraithmayr has authored more than 160 scientific publications and maintains a sustained record of peer-reviewed research. Representative publications reflect his contributions to lung transplantation, transplant immunology, and thoracic oncology.[1]

Research Impact

According to Scopus metrics, Jungraithmayr has accumulated 129 indexed documents, 2,929 citations, and an h-index of 28. These indicators demonstrate sustained scholarly influence within thoracic surgery, transplantation science, and oncology research.[1]

Beyond publication metrics, his impact is reflected through international teaching initiatives, reviewer responsibilities for leading journals, grant-review service for major funding agencies, editorial board memberships, and mentorship of emerging clinicians and scientists. His laboratory has trained investigators from numerous institutions across Europe, North America, and Asia, thereby extending the global reach of his methodological innovations.[1]

Award Suitability

Several factors support consideration of Wolfgang Jungraithmayr for a Lifetime Achievement Award. These include his longstanding record of scientific productivity, leadership of internationally recognized research programs, establishment of innovative experimental models, successful acquisition of competitive funding, extensive educational activities, and receipt of numerous international scientific distinctions. His contributions have influenced both clinical practice and experimental biomedical research, particularly in thoracic surgery and transplantation science.[1]

The cumulative scope of his achievements illustrates a sustained commitment to advancing medical knowledge, supporting scientific collaboration, and fostering the development of future generations of clinician-scientists.[2]

Conclusion

Wolfgang Jungraithmayr represents a notable figure in contemporary thoracic surgery and translational medicine. Through pioneering research, academic leadership, international educational engagement, and sustained scientific productivity, he has contributed significantly to the advancement of lung transplantation and thoracic oncology. His record of achievement, influence, and service provides a strong basis for recognition within the framework of a Lifetime Achievement Award.[1]

References

  1. Elsevier. (n.d.). Scopus Author Details: Wolfgang Jungraithmayr, Author ID 25621008100. Scopus. https://www.scopus.com/authid/detail.uri?authorId=25621008100
  2. Ohm B, Giannou AD, Harriman DI, Jungraithmayr WM, Zazara DE, et al. (2025). Chimerism and Immunological Tolerance in Solid Organ Transplantation. Immunologic Research. https://link.springer.com/article/10.1007/s00281-025-01052-x
  3. Moneke I, Ogutur ED, Kornyeva A, Jungraithmayr WM, Frye BC, et al. (2024). Donor Age Over 55 Is Associated With Worse Outcome in Lung Transplant Recipients With Idiopathic Pulmonary Fibrosis. BMC Pulmonary Medicine, 2024. https://link.springer.com/article/10.1186/s12890-024-03317-x
  4. Sander ML, Eulenburg V, Maeyashiki T, Jungraithmayr WM, Piegeler T, et al. (2024). Remote Kidney and Liver Injury After Transplantation of Lung Allografts in an Allogeneic Mouse Model. Transplantation Proceedings, 2024. DOI: https://doi.org/10.1016/j.transproceed.2024.10.020
  5. Coppens A, Verleden SE, Claes E, Voet H, Verleden GM, Lapperre TS, Yildirim AÖ, et al. (2024). Murine Orthotopic Lung Transplant Models: A Comprehensive Overview of Genetic Mismatch Degrees and Histopathological Insights Into Chronic Lung Allograft Dysfunction. American Journal of Transplantation, 2024. DOI: https://doi.org/10.1016/j.ajt.2024.07.033
  6. Jungraithmayr W. (2020). Novel Strategies for Endothelial Preservation in Lung Transplant Ischemia-Reperfusion Injury. Frontiers in Physiology, 2020. DOI: https://doi.org/10.3389/fphys.2020.581420

Qizhi Diao | Medicine and Dentistry | Research Excellence Award

Posted on by Phenomenological Research

Research Excellence Award

Qizhi Diao
Hainan Branch, Shanghai Children’s Medical Center, School of Medicine, Shanghai Jiao Tong University, China
Qizhi Diao
Affiliation Shanghai Jiao Tong University
Country China
Designation Professor
Scopus ID 52563308500
Documents 19
Citations 252
h-index 9
Subject Area Medicine and Dentistry
Event International Phenomenological Research Awards
ORCID 0000-0003-1121-4656

Qizhi Diao is a professor affiliated with the Hainan Branch of Shanghai Children’s Medical Center, School of Medicine, Shanghai Jiao Tong University, Sanya, China. His academic work has focused on the synthesis of functional nanomaterials, the construction of advanced clinical diagnostic sensors, and the development of nanocarrier-mediated therapeutic systems for biomedical applications. His research activities have contributed to innovations in biosensing technologies, point-of-care diagnostics, CRISPR/Cas-enabled sensing systems, and nanopharmaceutical delivery platforms.[1] Diao has participated in multiple nationally and provincially funded scientific projects related to cancer diagnostics, SARS-CoV-2 detection technologies, and exosome identification systems within nucleic acid assembly frameworks.[2]

Abstract

The academic contributions of Qizhi Diao are associated with interdisciplinary developments in nanomedicine, biosensor engineering, and clinical laboratory technologies. His research has emphasized the design of graphdiyne-based nanostructures, electrochemical sensing systems, nanozyme-assisted diagnostics, and portable point-of-care biosensing platforms. Through projects supported by the National Natural Science Foundation of China and regional scientific agencies, Diao has contributed to the development of technologies for detecting infectious diseases, circulating tumor cells, and gastric cancer biomarkers.[3] His work integrates materials science, clinical diagnostics, and biomedical engineering into translational research frameworks applicable to modern laboratory medicine.

Keywords

Nanomaterials; Graphdiyne; Clinical Diagnostic Sensors; CRISPR/Cas Technology; Electrochemical Biosensors; Nanopharmaceuticals; Targeted Drug Delivery; Nanozymes; Medical Laboratory Technology; Point-of-Care Diagnostics; Biomedical Engineering; Electrochemical Sensing.

Introduction

Recent advancements in biomedical engineering and nanotechnology have accelerated the development of highly sensitive diagnostic platforms and targeted therapeutic systems. Within this scientific context, Qizhi Diao has conducted research aimed at integrating nanomaterial synthesis with clinical laboratory applications. His work has addressed major challenges in biosensing accuracy, rapid pathogen detection, and nanocarrier-mediated therapeutic delivery systems.[4]

Qizhi Diao’s investigations into graphdiyne-based sensing systems and nanozyme catalytic materials have contributed to the broader understanding of electrochemical diagnostics and biosensor miniaturization. His projects have also focused on CRISPR/Cas-mediated detection systems capable of improving diagnostic sensitivity for infectious diseases and cancer-associated biomarkers.[5]

Research Profile

Qizhi Diao has maintained a long-term academic focus on the fabrication of functional nanomaterials, clinical diagnostic sensors, and nanocarrier-mediated drug delivery systems. His institutional affiliations include the Hainan Branch of Shanghai Children’s Medical Center and Shanghai Jiao Tong University School of Medicine.[1]

His completed and ongoing projects include:

  • Research on encoding for the identification of plasma exosome subtypes based on confined recognition and amplification systems within nucleic acid assembly frameworks funded by the National Natural Science Foundation of China.
  • Portable sensors for simultaneous detection of multiple gastric cancer biomarkers using CRISPR/Cas technology funded by the Hainan Provincial Health Commission.
  • Point-of-care quantitative detection systems for SARS-CoV-2 nucleic acids using graphdiyne sub-nanosheets supported by the Natural Science Foundation Project of Chongqing.
  • Novel 3D magnetic nanocomposites based on graphdiyne-MOFs for simultaneous capture and chemotherapy of circulating tumor cells in peripheral blood.
  • Development of graphdiyne-based systems for the detection of SARS-CoV-2 antigen biomarkers under emergency biomedical research initiatives.

His scientific profile additionally includes responsibilities as an ISO 15189 medical laboratory accreditation assessor and research review expert for multiple scientific organizations and governmental institutions in China.[6]

Research Contributions

Among Qizhi Diao’s reported scientific contributions is the synthesis of sub-nanoscale graphdiyne materials for the rapid and quantitative detection of Mycobacterium tuberculosis and drug-resistant genes.[7] This work supported the development of fluorescence sensing systems with improved analytical sensitivity and operational simplicity.

He also contributed to the preparation of core-shell nanozymes such as ZrFe-MOF@PtSn exhibiting strong peroxidase-like catalytic properties for biosensing applications. Additionally, his research integrated miRNA-initiated strand displacement amplification with CRISPR/Cas12a amplification strategies, nanozyme catalysis, and machine-learning-assisted electrochemical sensing systems.[8]

Qizhi Diao has further contributed to patents related to electrochemical immunosensors, medical testing oscillation devices, and laboratory inspection equipment. These developments reflect the translational dimension of his work in clinical laboratory technologies.[9]

Publications

Qizhi Diao has published research in internationally recognized journals focusing on nanotechnology, biomedical sensing, and clinical diagnostic systems. His publications explore graphdiyne-based fluorescent sensing platforms for detecting Mycobacterium tuberculosis and drug-resistant genes, nanoparticle-based drug delivery systems for cardiovascular diseases, and nanozyme-assisted biosensing technologies for rapid pathogen detection. He has also contributed to studies on high-porosity carbon electrocatalysts and amino-functionalized carbon nanodots for biomedical applications. His scholarly work integrates nanomaterials, electrochemical sensing, CRISPR/Cas technologies, and translational laboratory medicine, supporting advancements in point-of-care diagnostics, targeted therapeutics, and innovative clinical biosensor development.

Research Impact

The research activities of Qizhi Diao have contributed to interdisciplinary developments linking nanotechnology, laboratory medicine, and biomedical sensing systems. His work on graphdiyne nanostructures and nanozyme catalytic platforms has been associated with improved biosensor sensitivity and enhanced diagnostic performance in infectious disease detection.[10]

According to the provided academic indicators, his research record includes an h-index of 9 and more than 252 citations indexed through Scopus, in addition to reported Web of Science citations exceeding 300.[11] His collaborative work with organizations such as the Chinese Medical Doctor Association and the Chinese Medical Association has also supported laboratory medicine standardization and diagnostic research initiatives.

Award Suitability

The academic profile of Qizhi Diao demonstrates sustained engagement in translational biomedical research, particularly within nanomaterials, biosensors, and clinical diagnostics. His involvement in nationally funded scientific projects, patented technologies, and peer-reviewed publications indicates an active contribution to applied medical research and laboratory innovation.

His combination of scientific output, technical expertise, research leadership, and participation in accreditation and evaluation activities supports consideration for the Research Excellence Award under the International Phenomenological Research Awards framework.

Conclusion

Qizhi Diao has contributed to the advancement of nanotechnology-enabled diagnostic systems and biomedical sensing platforms through interdisciplinary scientific research. His work combines materials engineering, electrochemical sensing, nanozyme catalysis, and clinical laboratory applications into translational biomedical solutions. Through publications, funded research projects, patents, and scientific service roles, he has established a research profile connected to contemporary developments in medical diagnostics and nanomedicine.

References

  1. International Phenomenological Research Awards. (2026). Award nomination application form: Qizhi Diao. https://phenomenologicalresearch.com/
  2. National Natural Science Foundation of China. Research project information related to biomedical sensing and exosome identification systems.
  3. Diao Q. Research projects and biomedical sensing technologies associated with clinical diagnostics and nanomaterials research.
  4. Shanghai Jiao Tong University School of Medicine. Biomedical nanotechnology and laboratory medicine research activities.
  5. CRISPR/Cas biosensing applications in rapid diagnostic systems and molecular detection technologies.
  6. China National Accreditation Service for Conformity Assessment (CNAS). ISO 15189 medical laboratory accreditation activities and technical assessment programs.
  7. Chang F, Huang L, Guo C, Xie G, Li J, Diao Q. (2019). Graphdiyne-Based One-Step DNA Fluorescent Sensing Platform for the Detection of Mycobacterium tuberculosis and Its Drug-Resistant Genes. ACS Applied Materials & Interfaces. https://pubs.acs.org/doi/abs/10.1021/acsami.9b15248
  8. Yang F, Xue J, Wang G, Diao Q. (2022). Nanoparticle-based drug delivery systems for the treatment of cardiovascular diseases. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2022.999404
  9. Chinese patent documentation related to electrochemical immunosensors, laboratory inspection devices, and medical testing technologies.
  10. Feng T, Liao W, Li Z, Sun L, Shi D, Guo C, Huang Y, Wang Y, Cheng J, Li Y, Diao Q. (2017). Heavily Graphitic-Nitrogen Self-doped High-porosity Carbon for the Electrocatalysis of Oxygen Reduction Reaction. Nanoscale Research Letters. https://link.springer.com/article/10.1186/s11671-017-2364-6
  11. Elsevier. (n.d.). Scopus author details: Qizhi Diao, Author ID 52563308500. Scopus. https://www.scopus.com/authid/detail.uri?authorId=52563308500

Bing Han | Medicine and Dentistry | Outstanding Scientist Award

Posted on by Phenomenological Research

Dr.Bing Han | Medicine and Dentistry | Outstanding Scientist Award 

Dermatologist at The First Hospital of Jilin University | China

Dr. Bing Han is a medical researcher and clinician specializing in dermatological science with a strong foundation in advanced medical education and academic training. Dr. Bing Han has extensive professional experience integrating clinical practice with translational research, focusing on melanoma, vitiligo, and molecular mechanisms of skin disease progression. The research interests emphasize biomarker discovery, metabolic reprogramming, and therapeutic innovation in dermatology. With 99 scholarly documents, 1,291 citations from 1,231 documents, and an h-index of 22, Dr. Bing Han demonstrates sustained scientific impact and excellence in medical research.

Citation Metrics (Scopus)

1400

1000

600

200

0

Citations
1,291

Documents
99

h-index
22


View Scopus Profile

Featured Publications

Rolf Teschke | Medicine and Dentistry | Best Paper Award

Posted on by Phenomenological Research

Prof. Rolf Teschke | Medicine and Dentistry | Best Paper Award

Professor at Klinikum Hanau | Germany

Prof. Rolf Teschke is an internationally recognized expert in hepatology whose distinguished career has significantly influenced contemporary understanding of liver diseases, hepatotoxicity, and drug-induced liver injury. Educated at leading medical institutions and trained in internal medicine with specialization in gastroenterology and hepatology, he advanced early in his career through rigorous scientific and clinical environments that shaped his enduring interest in hepatic metabolism and toxicology. His research journey includes extensive work in experimental hepatology, where he contributed pivotal insights into microsomal ethanol-oxidizing systems, cytochrome P450 related pathways, and the biochemical mechanisms underlying alcohol-associated and toxin-induced liver damage. Over several decades, Prof. Rolf Teschke has held prominent academic and clinical positions, leading major medical departments and contributing to both patient care and research innovation. His expertise is particularly well known for advancing causality assessment methodologies in drug-induced liver injury, especially through his influential work with the RUCAM system, which has become a globally referenced tool in hepatotoxicity evaluation. Throughout his career, he has produced a substantial body of peer-reviewed literature, reflecting profound scientific productivity and impact. His publication record includes 171 documents, supported by 6,888 citations across 4,040 citing documents, and an impressive h-index of 48, underscoring the depth, relevance, and international recognition of his work. Prof. Rolf Teschke’s research interests span alcoholic liver disease, herbal and drug hepatotoxicity, biochemical enzymology, and clinical hepatology, integrating laboratory discoveries with real-world clinical applications to improve diagnostic standards and therapeutic strategies. He has authored and co-authored more than 250 publications, including articles, book chapters, and comprehensive reviews, contributing to foundational knowledge used by clinicians, toxicologists, and regulatory bodies worldwide. In addition to research, he has served in editorial roles for several journals, helping guide scientific discourse in hepatology and liver toxicology. Overall, Prof. Rolf Teschke’s career reflects a sustained commitment to advancing scientific excellence, improving patient outcomes, and shaping global best practices in the study of liver injury, marking him as one of the leading contributors to modern hepatology.

Profile; Scopus | Orcid

Featured Publications:

Teschke, R. Drug-Induced Autoimmune Hepatitis by Varenicline and Infliximab as a Continuous Disease Spectrum with Two Different Flares: Acute Liver Injury Followed by Hepatic Autoimmunity. Review.
Annotation: Discusses two-step autoimmune hepatitis triggered by pharmaceutical agents, highlighting diagnostic and clinical implications.

Teschke, R. Acute Liver Failure with Determinate rather than Indeterminate Etiology Facilitates Therapy and May Avoid Liver Transplantation: A Critical Analysis. Review.
Annotation: Evaluates clinical outcomes in acute liver failure and argues the benefits of precise etiological identification.

Teschke, R., et al. Drug-Induced Autoimmune Hepatitis: Robust Causality Assessment Using Two Different Validated and Scoring Diagnostic Algorithms. Review.
Annotation: Compares two validated diagnostic algorithms to strengthen causality assessment in drug-induced autoimmune hepatitis.

Teschke, R. Immunology Highlights of Four Major Idiosyncratic DILI Subtypes Verified by the RUCAM: A New Evidence-Based Classification. Review.
Annotation: Proposes an evidence-based immunological classification for idiosyncratic drug-induced liver injury (DILI).

Teschke, R., et al. Metabolic Mysteries of Copper Dysregulation in Wilson Disease. Review.
Annotation: Explores metabolic pathways and unresolved mechanisms underlying copper dysregulation in Wilson’s disease.

Teschke, R., et al. Open Questions on How Metabolic Dysfunction-Associated Steatotic Liver Disease Shapes the Course of Drug-Induced Liver Injury. Letter.
Annotation: Raises key unresolved scientific and clinical questions on the interaction between MASLD and DILI.

Teschke, R. Liver Injury in Immune Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Five New Classification Types. Review.
Annotation: Introduces a new five-type classification system for liver injury associated with severe immune-mediated skin reactions.

Teschke, R. Acute Liver Failure Due to Assumed Drug Induced Liver Injury but Lack of Any Validated Causality Algorithm: Evidence by 36 Cohort Reports with 21,709 Cases. Review.
Annotation: Critically analyzes large cohorts revealing gaps in validated causality assessment for assumed DILI-related acute liver failure.

Teschke, R. Idiosyncratic Hepatocellular Drug-Induced Liver Injury by Flucloxacillin with Evidence Based on RUCAM and HLA B57:01 Genotype.* Review.
Annotation: Examines metabolic and immune mechanisms underlying flucloxacillin-induced hepatocellular injury.

Teschke, R., et al. Successful Corticosteroid Therapy for Severe Liver Injury Secondary to Herbal Traditional Chinese Medicine Mega Defends X: A Case Report. Article, 2024.
Annotation: Documents a clinically significant case showing steroid responsiveness in herb-induced liver injury assessed by updated RUCAM.

Serap Ozdemir | Nursing and Health Professions | Best Researcher Award

Posted on by Phenomenological Research

Dr. Serap Ozdemir | Nursing and Health Professions | Best Researcher Award

Assistant Professor at Gaziantep University | Turkey

Dr. Serap Özdemir is a dedicated and forward-thinking academic whose contributions to nursing and health professions reflect a continuous commitment to advancing evidence-based pediatric and neonatal care. With a strong educational foundation culminating in doctoral-level training in child health and disease nursing, she has built a research portfolio focused on enhancing clinical outcomes for newborns, preterm infants, and children within diverse healthcare settings. Her professional experience includes teaching, academic leadership, and active involvement in multidisciplinary research collaborations that integrate nursing expertise with emerging scientific and technological innovations. Over the course of her academic career, nominee Dr. Serap Özdemir has developed a growing publication record consisting of 16 scholarly documents that have collectively earned 44 citations by 43 external publications, contributing to an h-index of 3 and demonstrating measurable influence within her field. Her research interests encompass neonatal intensive care, developmental health, the improvement of comfort and stress parameters in early infancy, and the application of modern data-driven tools such as artificial intelligence to clinical assessment and decision-making. She has taken part in multiple randomized controlled studies and instrument development projects designed to enhance the measurement of nursing performance, care quality, and professional competency in pediatric nursing environments. Her scientific output extends to peer-reviewed journals indexed in major research databases, as well as contributions to academic books and professional texts that support the dissemination of current best practices to nursing practitioners and students. Additionally, her work reflects a commitment to international engagement through collaborations, conference participation, and involvement in professional associations supporting knowledge exchange and healthcare improvement. Through these combined efforts, Dr. Serap Özdemir continues to shape contemporary thinking around neonatal and pediatric care, promoting research-driven nursing standards that emphasize compassionate, culturally sensitive, and scientifically validated interventions. She remains devoted to advancing healthcare delivery through continuous scholarship, the refinement of clinical methodologies, and the pursuit of innovative interdisciplinary solutions that support improved outcomes for vulnerable patient populations. Her ongoing work reinforces the essential role of nursing research in improving health systems globally and contributes meaningfully to the development of a more advanced, responsive, and patient-centered model of pediatric and neonatal care.

Profile: Scopus | Google Scholar

Featured Publicaations:

Özdemir, S., & Balcı, S. (2024). The effect of tub bathing on the skin and bilirubin levels of babies receiving tunnel and light-emitting diode phototherapies: A randomized controlled trial. Advances in Skin and Wound Care, 37(7), 1–9.

Özdemir, S., & Elmaoğlu, E. (2024). Psychometric properties of the pediatric ward nurses’ caring self-efficacy scale: A Turkish validity and reliability study. Journal of Pediatric Nursing, 75, 41–48.

Özdemir, S., & Küçük, F. (2023). The effect of the facilitated tucking after vaginal delivery on stress, comfort, and physiological parameters of late preterm infants: A randomized controlled trial. Iranian Journal of Neonatology, 14(4), 12–20.

Özdemir, S., & Sevinç, S. (2023). Correlation between cultural competence, xenophobia, and attitudes towards brain drain in nursing students. Nurse Education Today, 131, Article 105963.

Özdemir, S., & Elmaoğlu, E. (2023). Validity and reliability of the distracting ingenuity promotion scale in pediatric nurses. HUHEMFAD-JOHUFON, 10(3), 230–236.

Özdemir, S. (2022). Design of autonomous controlled integrated system for increasing comfort in newborns: Interdisciplinary collaboration between engineering and nursing studies. Dentistry & Medical Research, 8(2), 2–6.

Özdemir, S. (2022). Interdisciplinary collaboration between engineering and nursing: Baby crying analyzing using MATLAB graphical user interface. Biomed Biotechnology Research Journal, 6(3), 410–415.

Özdemir, S., & Yılmaz E. Ç. (2022). Interdisciplinary collaboration between engineering and nursing on baby crying analyzing and classification: A biotechnology study. Journal of Preventive, Diagnostic and Treatment Strategies in Medicine, 1(2), 82–87.

Cristina Maria Del Prete | Medicine and Dentistry | Women Researcher Award

Posted on by Phenomenological Research

Dr. Cristina Maria Del Prete | Medicine and Dentistry | Women Researcher Award 

Rehabilitation Department Chair at Local Health Authority Italy

Dr. Cristina Maria Del Prete is a recognized professional in the field of Physical and Rehabilitation Medicine, known for her commitment to advancing innovative healthcare models, interdisciplinary rehabilitation practices, and measurable improvements in patient quality of life. She completed comprehensive medical education and specialized training in rehabilitation medicine, followed by multiple advanced executive and managerial qualifications focused on healthcare systems, organizational leadership, digital transformation, and strategic management. Her education laid a strong foundation for a career that has spanned clinical practice, healthcare administration, academic teaching, and national health policy participation. Over the years, she has held progressive leadership roles within major public healthcare structures, directing rehabilitation departments, coordinating multidisciplinary teams, and overseeing complex service networks involving hospital- and community-based rehabilitation centers. Her responsibilities have included workforce management, budget oversight, strengthening patient-care pathways, improving standards of disability support, and enhancing regional service delivery in alignment with evolving healthcare regulations. She has also actively contributed to national and regional scientific boards, steering committees, and professional societies focused on improving spasticity management, supporting patients with neurological conditions, addressing musculoskeletal pain, and advancing gender-inclusive perspectives within modern healthcare. Her research output reflects a strong blend of clinical relevance and academic rigor, focusing on post-stroke rehabilitation, botulinum toxin interventions in neuromotor disorders, gait analysis, scoliosis management, family coping mechanisms in the context of disability, and the psychological dynamics influencing care outcomes. Her published studies in international peer-reviewed journals demonstrate a dedication to evidence-based rehabilitation, resulting in 63 citations from 55 documents, 7 published scientific works, and an h-index of 4. She has also contributed extensively to academic progress through university teaching appointments across multiple medical programs, where she has trained students in foundational and advanced principles of rehabilitation medicine. International clinical training and professional development programs have further enhanced her expertise and broadened her exposure to advanced rehabilitative technologies, patient-centered methodologies, and global best practices. Throughout her career, she has remained consistently committed to improving health system performance, innovating care delivery frameworks, and conducting research that informs more efficient, equitable, and clinically effective rehabilitation services. Her professional journey reflects a continuous dedication to advancing healthcare quality, supporting both patients and practitioners, and strengthening the scientific foundations of modern rehabilitation.

Profile: Scopus | Google Scholar

Featured Publications:

Del Prete, C. M. (2025). Determinants of sibling relationships in the context of mental disorders. PLoS One.

Del Prete, C. M. (2025). Siblings of persons with disabilities: A systematic integrative review of the empirical literature. Clinical Child and Family Psychology Review.

Del Prete, C. M. (2023). Parentification, distress, and relationships with parents as factors shaping relationships in families with disability. Frontiers in Psychiatry.

Del Prete, C. M. (2022). An observational cross-sectional study of gender and disability as determinants of person-centered medicine in botulinum neurotoxin treatment of upper motoneuron syndrome. Toxins.

Del Prete, C. M. (2022). Brace treatment in adolescent idiopathic scoliosis: A rehabilitative point of view. International Journal of Environmental Research and Public Health.

Del Prete, C. M. (2021). Early botulinum toxin type A injection for post-stroke spasticity: A longitudinal cohort study. Toxins.

Del Prete, C. M. (2022). Efficacy of ultrasound-guided percutaneous lavage and biocompatible electrical neurostimulation in calcific rotator cuff tendinopathy. International Journal of Environmental Research and Public Health.

Del Prete, C. M. (2004). Conservative rehabilitative treatment of facial nerve injuries: A critical literature review. Europa Medicophysica.

Del Prete, C. M. (2002). Outcome research in adults with neurological disability. Europa Medicophysica.

Del Prete, C. M. (2001). Therapeutic water exercise in patients with hip arthroplasty. Europa Medicophysica.

Lukas Prantl | Medicine and Dentistry | Best Researcher Award

Posted on by Phenomenological Research

Prof. Dr. Lukas Prantl | Medicine and Dentistry | Best Researcher Award

Applied Stem Cell Research Center at Universität Regensburg | Germany

Prof. Dr. Lukas Prantl is an accomplished academic leader and internationally recognized expert in plastic, aesthetic, and reconstructive surgery, currently serving at the University of Regensburg, Germany. His career reflects a strong blend of clinical innovation, academic excellence, and translational research impact. Educated in medicine and advanced surgical sciences across prestigious European institutions, he holds dual doctoral degrees and a master’s in health business administration, which support his interdisciplinary approach to healthcare leadership. Throughout his professional journey, he has established and directed advanced centers dedicated to plastic, hand, and reconstructive surgery, as well as the Applied Stem Cell Research Center, fostering groundbreaking research in regenerative medicine. His scientific interests focus on adipose-derived stem cells, tissue regeneration, microcirculation, and innovative reconstructive techniques that integrate stem cell technology into clinical applications. Among his notable contributions is the development of the Cell Enriched Lipotransfer method, a pioneering advancement that enhances the success rate of fat grafting and tissue restoration. His prolific academic record includes 412 peer-reviewed publications, 7,550 citations from 6,310 documents, and an h-index of 40, reflecting the global impact and recognition of his research. Beyond his scientific achievements, he has held leadership positions in major national and international surgical societies, contributing to the advancement of standards, education, and ethics in surgery. As an editor and reviewer for leading medical journals and funding bodies, his expertise continues to guide the development of innovative research and surgical techniques worldwide. His commitment to academic mentorship and the integration of evidence-based medicine into practice has shaped new generations of clinicians and researchers. Through his exceptional contributions to clinical excellence, scientific discovery, and institutional leadership, Prof. Dr. Lukas Prantl stands as a driving force in shaping the future of regenerative and reconstructive medicine, continually pushing the boundaries of surgical science and patient-centered innovation.

Profile: Scopus | Orcid | Google Scholar

Featured Publications:

  • Chrobot, N., Unbehaun, P., Frank, K., Hartmann, Prantl, L. (2025). Smartphone-based 3D surface imaging: A new frontier in digital breast assessment? Journal of Clinical Medicine.

  • Neuwieser, H., Jami, N. V. S., Meier, Prantl, L. (2025). Interpreting venous and arterial ulcer images through the Grad-CAM lens: Insights and implications in CNN-based wound image classification. Diagnostics.

  • Schimanski, T., Scheel-Platz, Prantl, L. (2025). CELT Fat increases the metabolic activity as well as the SVF-yield significantly when compared to CELT fat, even after cryopreservation with DMSO. Cells.

  • Loucas, R., Loucas, Prantl, L. (2025). Histology and immunohistochemistry of adipose tissue: A scoping review on staining methods and their informative value.

  • Diesch, S., Frank, K., Brebant, Prantl, L. (2025). Subject-reported satisfaction after cell-enriched lipotransfer (CELT) for lip augmentation. Aesthetic Plastic Surgery.

  • Biermann, N., Eibl, D., Mueller, Prantl, L. (2024). Biomarker-guided acute kidney injury risk assessment under liberal versus restrictive fluid therapy–the prospective-randomized MAYDAY-trial.

  • Zocchi, M.Prantl, L. (2024). Potential benefits of adipose-derived SVF and MSCs to regenerate damaged tissues from alloplastic synthetic materials.

  • Kuehlmann, B., Bonham, C. Gurtner,Prantl, L. (2023). MMP9 as a potential biomarker in human implant-induced fibrotic capsules: A systematic analysis and biomarker study.

  • Knoedler, L., Odenthal, J. F., Prantl, Knoedler, S. A. (2023). Artificial Intelligence-Enabled simulation of gluteal augmentation: A helpful tool in preoperative outcome simulation.

  • Diesch, S., Anders, M., Prantl, Brébant, V. (2023). Factors influencing the shape, size, symmetry and scar of the nipple-areola complex after bilateral reduction mammoplasty.

Iker Alonso González | Medicine and Dentistry | Best Researcher Award

Posted on by Phenomenological Research

Mr. Iker Alonso González | Medicine and Dentistry | Best Researcher Award 

FACULTATIVO ESPECIALISTA MEDICO-TECNICO EN MICROBIOLOGÍA Y PARASITOLOGÍA at Cruces University Hospital | Spain

Mr. Iker Alonso González is a dedicated researcher and professional in the field of microbiology and clinical parasitology, recognized for his growing contributions to medical and pharmaceutical sciences. He holds a degree in Pharmacy from the University of the Basque Country (UPV/EHU) and has further specialized in Microbiology and Clinical Parasitology at Cruces University Hospital, where he continues to advance his expertise in infectious disease research and diagnostics. His professional experience at Osakidetza the Basque Health Service combines clinical practice with applied research, focusing on microbial resistance, infectious disease control, and antibiotic stewardship. He has presented numerous research communications, including fourteen posters and two oral presentations at the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), addressing critical topics such as antimicrobial resistance patterns in Shigella spp. and the clinical impact of post-treatment uroculture interventions. His scientific publication, “Multiresistant Aeromonas hydrophila bacteremia,” published in Enferm Infecc Microbiol Clin (Engl Ed), reflects his analytical approach and contribution to understanding emerging multidrug-resistant pathogens. His current research interests center around the development of evidence-based antimicrobial protocols, optimization of laboratory diagnostics, and epidemiological monitoring of infectious diseases in clinical settings. Mr. Iker Alonso González’s participation in national research forums and professional societies highlights his commitment to academic collaboration and scientific advancement. His early scholarly impact is reflected in his record of 2 citations by 2 documents, 3 published works, and an h-index of 1, indicating a promising trajectory in medical research. He is also engaged in continuous professional development, ensuring alignment with global standards in clinical microbiology and pharmaceutical practice. Through his rigorous research, clinical application, and scholarly engagement, Mr. Iker Alonso González exemplifies the integration of scientific inquiry and healthcare innovation, contributing to the ongoing efforts to enhance antimicrobial stewardship and patient outcomes in contemporary medicine.

Profile: Scopus

Featured Publications:

  • Alonso-González, I. (2025). Upper limb abscess due to an unusual Clostridium species in an immunocompetent child. Enfermedades Infecciosas y Microbiología Clínica.

  • Alonso-González, I. (2023). Sensitivity profile of Shigella spp. isolates in patients with travelers’ diarrhea in a tertiary hospital in the period 2017–2022. Presented at the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC).

  • Alonso-González, I. (2023). Impact of a PROA intervention on the request of non-proven post-treatment control urocultures. Presented at the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC).

  • Alonso-González, I. (2022). Multiresistant Aeromonas hydrophila bacteremia. Enfermedades Infecciosas y Microbiología Clínica

 

Zsuzsanna Zsengeller | Medicine and Dentistry | Best Researcher Award

Posted on by Phenomenological Research

Dr. Zsuzsanna Zsengeller | Medicine and Dentistry | Best Researcher Award 

Assistant professor at Beth Israel Deaconess Medical Center | United States

Dr. Zsuzsanna Zsengeller is a distinguished medical scientist whose career spans clinical medicine, molecular biology, and translational research. She has established herself as a global leader in the investigation of preeclampsia, mitochondrial dysfunction, and kidney-related disorders. With appointments at world-renowned institutions, she has advanced knowledge in gene therapy, molecular signaling, and maternal-fetal health. Her professional journey demonstrates a seamless integration of clinical insight and laboratory research, producing innovative therapeutic approaches. Through consistent scholarly output, grant leadership, and mentorship of future scientists, Dr. Zsuzsanna Zsengeller embodies excellence in academic medicine and translational science, with her work directly impacting patient health worldwide.

Profile:

Orcid

Education:

Dr. Zsuzsanna Zsengeller earned her Doctor of Medicine degree in General Medicine, followed by a Ph.D. in Medical Science with a strong foundation in microbiology. Her academic path was marked by a commitment to understanding complex disease mechanisms through both experimental and clinical approaches. Her postgraduate training included prestigious postdoctoral fellowships in pulmonary biology and respiratory diseases, where she refined her expertise in molecular and cellular biology. These academic experiences provided the groundwork for her lifelong research into oxidative stress, immune signaling, and vascular biology, ultimately shaping her into a well-recognized expert in mitochondrial and maternal health research.

Experience:

Dr. Zsuzsanna Zsengeller has extensive experience as both a clinician and scientist, having held positions across leading hospitals, research institutions, and industry collaborations. Her work includes significant contributions to pulmonary biology, renal pathology, and preeclampsia research. She has served in roles as staff scientist, senior scientist, consultant, and academic faculty member, currently serving as Assistant Professor of Medicine at Harvard Medical School. Her collaborations with multidisciplinary teams have resulted in advancements in therapeutic strategies for cardiovascular, renal, and maternal health. With experience in academia, industry, and clinical translation, she has built a unique career that bridges discovery and application.

Research Interest:

Dr. Zsuzsanna Zsengeller’s research interests center on the pathogenesis and treatment of preeclampsia, kidney disease, and mitochondrial dysfunction. She investigates redox biology, nitric oxide modulation, and oxidative stress pathways to understand how cellular signaling impacts maternal and fetal outcomes. Her translational studies have examined novel dual-function redox modulators, antioxidants, and mitochondrial-targeted therapies. Beyond maternal health, her work extends into nephrology and cardiovascular disease, with particular focus on mechanisms of APOL nephropathy and endothelial dysfunction. Through advanced molecular techniques and therapeutic modeling, her research seeks to translate laboratory discoveries into clinical strategies, offering hope for improved patient outcomes worldwide.

Awards and Honors:

Dr. Zsuzsanna Zsengeller has been recognized with numerous honors that reflect her leadership in biomedical science and translational medicine. She has received institutional research funding awards, including competitive support for her pioneering work on mitochondrial-targeted antioxidants for preeclampsia therapy. Her contributions have also been acknowledged through awards from scientific societies, highlighting her excellence in poster presentations, mentorship, and innovative project design. Her research projects have consistently received funding from federal agencies and medical foundations, underscoring the clinical relevance and impact of her work. These awards honor her as a trailblazer in developing therapies addressing urgent global health challenges.

Publications:

Title: Development of Diaryl Hydrazones for Alleviation of Mitochondrial Oxidative Stress in Preeclampsia
Year of Publication: 2025
Citation: 1

Title: Gasdermin D deletion prevents liver injury and exacerbates extrahepatic damage in a murine model of alcohol-induced ACLF
Year of Publication: 2025
Citation: 1

Title: A Novel Multi-organ Male Model of Alcohol-induced Acute-on-chronic Liver Failure Reveals NET-mediated Hepatocellular Death, Which is Prevented by RIPK3 Inhibition
Year of Publication: 2025
Citation: 5

Title: Differing sensitivities to angiotensin converting enzyme inhibition of kidney disease mediated by APOL1 high-risk variants G1 and G2
Year of Publication: 2024
Citation: 5

Title: Solvent- and Catalyst-Free Environmentally Benign High Hydrostatic Pressure-Assisted Synthesis of Bioactive Hydrazones and the Evaluation of Their Stability Under Various Storage Conditions
Year of Publication: 2024
Citation: 3

Title: A Novel Dual-Function Nitric Oxide Donor Therapy for Preeclampsia—A Proof-of-Principle Study in a Murine Model
Year of Publication: 2023
Citation: 3

Title: Hepatocyte nuclear factor 4α mediated quinolinate phosphoribosylltransferase (QPRT) expression in the kidney facilitates resilience against acute kidney injury
Year of Publication: 2023
Citation: 8

Conclusion:

Dr. Zsuzsanna  Zsengeller stands as a pioneering physician-scientist whose research has transformed the understanding of oxidative stress, mitochondrial dysfunction, and maternal-fetal disorders. Her leadership in translational medicine continues to advance new therapies that address major public health burdens, particularly preeclampsia and kidney disease. Through groundbreaking research, impactful publications, and mentorship of future leaders, she exemplifies the highest standards of academic and clinical excellence. Her career demonstrates how dedication to discovery can be translated into real-world medical advancements, making her a highly deserving candidate for prestigious recognition in biomedical and clinical research innovation.

Jiang Haoran | Tissue Engineering | Best Researcher Award

Posted on by Phenomenological Research

Dr. Jiang Haoran | Tissue Engineering | Best Researcher Award

Doctoral candidate at Department of Orthopedics and Trauma, Peking University People’s Hospital, China.

Dr. Haoran Jiang 🎓 is a dedicated researcher in the field of tissue engineering 🧬, currently pursuing his doctorate at Peking University 🏛️ and affiliated with the Department of Orthopedics and Trauma at Peking University People’s Hospital 🏥. His groundbreaking research focuses on the therapeutic potential of nano-sustained-release factors for bone scaffolds 🦴, addressing key clinical challenges such as insufficient bioactivity in biomedical implants. Dr. Jiang’s work has been featured in reputed scientific journals 📘 and demonstrates a strong commitment to improving orthopedic treatment outcomes through innovative nanomaterial-based approaches ⚗️🔬.

Professional Profile:

ORCID

Suitability for Best Researcher Award – Dr. Haoran Jiang

Dr. Haoran Jiang is a highly deserving candidate for the Best Researcher Award due to his pioneering research in tissue engineering and nanotechnology. His work on developing nano-sustained-release bone scaffolds has the potential to significantly enhance the effectiveness of orthopedic implants, a field that addresses critical challenges in patient recovery and treatment outcomes. Dr. Jiang’s strong academic foundation, innovative contributions to biomaterials, and demonstrated ability to bridge basic science with clinical applications make him an outstanding researcher.

🎓 Education and Experience

  • 🎓 Doctoral Candidate at Peking University, China

  • 🏥 Researcher at the Department of Orthopedics and Trauma, Peking University People’s Hospital

  • 🔬 Conducting research on nano-sustained-release bone scaffolds for therapeutic applications

  • 📘 Published in Journal of Functional Biomaterials (SCI/Scopus Indexed)

  • 🧪 Involved in industry-relevant project: Mesoporous Nanomaterials for Bone Tissue Engineering

🚀 Professional Development

Dr. Haoran Jiang has demonstrated strong professional growth through his focus on translational biomedical research 🧬 that bridges fundamental science with clinical applications 🏥. His work on nano-sustained-release scaffolds ⚗️ addresses real-world problems in orthopedics, offering innovative strategies to improve the performance of bone implants 🦴. Publishing in reputable journals 📄 and contributing to key projects, he showcases a proactive approach in research development. Dr. Jiang is committed to exploring clinically adaptable solutions that can meet regulatory standards and enhance patient recovery outcomes 💉. His ongoing pursuit of excellence reflects his potential to become a leading voice in tissue engineering 🧠.

🔍 Research Focus Category

Dr. Jiang’s research lies at the intersection of tissue engineering, nanotechnology, and regenerative medicine 🧬🦠. His core focus is on the design and development of bone scaffolds integrated with nano-sustained-release systems for efficient delivery of therapeutic agents 💊. This category of research addresses unmet clinical needs in orthopedic treatments 🦴 by enhancing scaffold bioactivity and healing efficacy. With a particular emphasis on biocompatibility and clinical translation, his work seeks to optimize commonly used biomaterials to overcome current limitations in medical implants 🧪. The research is innovative, application-driven, and aims to bridge the lab-to-clinic gap in healthcare delivery 🏥🔬.

🏅 Awards and Honors

  • 🏅 First-author publication in Journal of Functional Biomaterials (2025)

  • 🧠 Recognized for innovative contributions in tissue engineering and orthopedic nanomedicine

  • 🧾 Listed in ORCID registry for global academic visibility

  • 📘 Publication indexed in SCI and Scopus, validating research excellence

Publication Top Notes

📄 Therapeutic Potential of Nano-Sustained-Release Factors for Bone Scaffolds

Conclusion

Dr. Haoran Jiang’s innovative contributions to tissue engineering and regenerative medicine solidify his candidacy for the Best Researcher Award. His research is not only groundbreaking in the scientific community but is also poised to make a lasting impact on clinical orthopedic treatments, bridging the gap between laboratory research and patient care. His dedication to advancing nanotechnology-based solutions for bone scaffolds places him at the forefront of this rapidly advancing field.